​

Monte Rosa Therapeutics Ownership | Who Owns Monte Rosa Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Monte Rosa Therapeutics Ownership Summary

Monte Rosa Therapeutics is owned by 24.30% institutional investors, 0.69% insiders, and 75.01% retail investors. Nea management company is the largest institutional shareholder, holding 9.36% of GLUE shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.74% of its assets in Monte Rosa Therapeutics shares.

GLUE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMonte Rosa Therapeutics24.30%0.69%75.01%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company7.69M9.36%$57.00M
Bvf inc/il5.66M6.89%$41.94M
Versant venture management5.65M6.88%$41.89M
Baker bros. advisors lp4.92M5.98%$36.43M
Price t rowe associates inc /md/4.64M5.64%$34.36M
Blackrock funding, inc. /de3.82M4.64%$28.27M
Suvretta capital management3.36M4.09%$24.90M
Blackrock2.36M3.92%$8.83M
Vanguard group2.99M3.64%$22.15M
Fmr2.81M3.42%$20.84M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management5.65M19.72%$41.89M
Nea management company7.69M3.13%$57.00M
Aisling capital management lp1.47M2.39%$10.91M
Bvf inc/il5.66M1.70%$41.94M
Rangeley capital113.00K0.72%$837.33K
Silverarc capital management694.94K0.69%$5.15M
Suvretta capital management3.36M0.64%$24.90M
Parkwood708.00K0.48%$5.25M
Alphabet1.46M0.45%$10.85M
Vestal point capital, lp800.00K0.27%$5.93M

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp800.00K0.27%800.00K
Silverarc capital management694.94K0.69%694.94K
Fmr2.81M0.00%524.22K
Marshall wace, llp902.83K0.01%456.75K
Norges bank445.87K0.00%445.87K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---3.73M
Price t rowe associates inc /md/4.64M0.00%-1.69M
Readystate asset management lp---287.00K
Goldman sachs group101.14K0.00%-247.06K
Renaissance395.73K0.00%-219.37K

New Positions

HolderShares% AssetsChangeValue
Vestal point capital, lp800.00K0.27%800.00K$5.93M
Silverarc capital management694.94K0.69%694.94K$5.15M
Norges bank445.87K0.00%445.87K$3.09M
Jane street group307.05K0.00%307.05K$2.28B
Adar1 capital management215.75K0.15%215.75K$1.60M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Us bancorp \de\-26.00
Capital performance advisors llp-29.00
Gamma investing-80.00
Skopos labs-92.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202547-59.83%19,971,709-67.89%240.42%21-72.37%16-11.11%
Jun 30, 20251167.41%62,164,3354.44%751.44%7570.45%18-60.87%
Mar 31, 20256-94.44%15,774,831-74.13%190.35%3-95.77%1-94.12%
Dec 31, 202455-34.52%25,603,232-48.56%310.85%40-25.93%4-66.67%
Sep 30, 2024849.09%49,773,7858.59%601.47%5414.89%12-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
US Small-Cap Growth II Equity Comp2.91M4.74%-312.26K
T. Rowe Price New Horizons2.84M4.59%-77.70K
Vanguard Total Stock Mkt Idx Inv1.88M3.05%-41.40K
HBM Healthcare Investments AG Ord1.41M2.29%-
FIAM Small Cap Core CIT Cl B1.26M2.04%755.07K
iShares Russell 2000 ETF1.10M1.78%-
T. Rowe Price Health Sciences1.04M1.69%95.09K
Fidelity Growth Compy Commingled Pl O970.82K1.58%-
T. Rowe Price New Horizons Tr-A902.11K1.47%14.92K
T. Rowe Price New Horizons Tr-Z887.19K1.44%1.28K

Recent Insider Transactions

DateNameRoleActivityValue
Jun 03, 2025Dunn Edmund Principal Accounting OfficerSell$9.17K
Mar 24, 2025Leo Chandra P.-Buy$58.38K
Oct 29, 2024Versant Venture Capital VI, L.P.-Sell$146.79K
Oct 28, 2024Versant Venture Capital VI, L.P.-Sell$869.24K
Oct 29, 2024Versant Venture Capital VI, L.P.-Sell$475.01K

Insider Transactions Trends

DateBuySell
2025 Q2-1
2025 Q11-
2024 Q4-3
2024 Q3-5
2024 Q2-1

GLUE Ownership FAQ

Who Owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics shareholders are primarily institutional investors at 24.30%, followed by 0.69% insiders and 75.01% retail investors. The average institutional ownership in Monte Rosa Therapeutics's industry, Biotech Stocks , is 45.24%, which Monte Rosa Therapeutics falls below.

Who owns the most shares of Monte Rosa Therapeutics?

Monte Rosa Therapeutics’s largest shareholders are Nea management company (7.69M shares, 9.36%), Bvf inc/il (5.66M shares, 6.89%), and Versant venture management (5.65M shares, 6.88%). Together, they hold 23.12% of Monte Rosa Therapeutics’s total shares outstanding.

Does Blackrock own Monte Rosa Therapeutics?

Yes, BlackRock owns 3.92% of Monte Rosa Therapeutics, totaling 2.36M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 8.83M$. In the last quarter, BlackRock increased its holdings by 53.08K shares, a 2.30% change.

Who is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.72% of its assets in 5.65M Monte Rosa Therapeutics shares, valued at 41.89M$.

Who is the top mutual fund holder of Monte Rosa Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Monte Rosa Therapeutics shares, with 4.74% of its total shares outstanding invested in 2.91M Monte Rosa Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools